Section 6 of 6
References
177 sources
- Aelvoet et al. (2022) (opens in a new tab)
- Agresta et al. (2018) (opens in a new tab)
- Alberta Health Services clinical practice guideline SAR-004 (2025) (opens in a new tab)
- Anneberg et al. (2022) (opens in a new tab)
- Aung et al. (2018) (opens in a new tab)
- Bektas et al. (2023) (opens in a new tab)
- Bocale et al. (2011) (opens in a new tab)
- Bonvalot et al. (2023) (opens in a new tab)
- Bouhamama et al. (2023) (opens in a new tab)
- Brueckl et al. (2005) (opens in a new tab)
- Bui et al. (2025) (opens in a new tab)
- Cazzato et al. (2022) (opens in a new tab)
- Chetan et al. (2025) (opens in a new tab)
- Chugh et al. (2025) (opens in a new tab)
- Chugh et al. (2026) (opens in a new tab)
- Cigna nirogacestat coverage policy (2025) (opens in a new tab)
- ClinicalTrials.gov NCT01986218 (opens in a new tab)
- ClinicalTrials.gov NCT02476305 (opens in a new tab)
- ClinicalTrials.gov NCT04871282 (opens in a new tab)
- ClinicalTrials.gov NCT04871282 version 35 (opens in a new tab)
- ClinicalTrials.gov NCT04871282 version 37 (opens in a new tab)
- ClinicalTrials.gov NCT06677996 (opens in a new tab)
- ClinicalTrials.gov NCT06841315 (opens in a new tab)
- ClinicalTrials.gov NCT06845852 (opens in a new tab)
- ClinicalTrials.gov NCT06855264 (opens in a new tab)
- ClinicalTrials.gov NCT07610005 (opens in a new tab)
- Cojocaru et al. (2022) (opens in a new tab)
- Colombo et al. (2013) (opens in a new tab)
- Colombo et al. (2022) (opens in a new tab)
- Colombo et al. (2025) (opens in a new tab)
- Colombo et al. (2026) (opens in a new tab)
- Constantinidou et al. (2009) (opens in a new tab)
- Costa et al. (2025) (opens in a new tab)
- Crago et al. (2013) (opens in a new tab)
- Debaudringhien et al. (2022) (opens in a new tab)
- Desmoid Tumor Working Group (2020) (opens in a new tab)
- Dossa et al. (2026) (opens in a new tab)
- Drabbe et al. (2023) (opens in a new tab)
- Elnekave et al. (2022) (opens in a new tab)
- EMA Ogsiveo EPAR (2025) (opens in a new tab)
- EMA orphan designation EU/3/25/3127 (2025) (opens in a new tab)
- EU Clinical Trials Information System 2024-515909-26-00 (opens in a new tab)
- EU Clinical Trials Information System 2024-515909-26-00 API record (opens in a new tab)
- Express Scripts nirogacestat criteria (2023) (opens in a new tab)
- FDA guidance, E14 clinical evaluation of QT/QTc interval prolongation (2005) (opens in a new tab)
- FDA orphan drug designation record for varegacestat (2023) (opens in a new tab)
- Federman (2022) (opens in a new tab)
- FEP Blue nirogacestat policy 5.21.217 (2026) (opens in a new tab)
- Fernandez et al. (2023) (opens in a new tab)
- Fetterly et al. (2026) (opens in a new tab)
- Fiore et al. (2014) (opens in a new tab)
- Fiore et al. (2015) (opens in a new tab)
- Fiore et al. (2025) (opens in a new tab)
- Florida Medicaid oncology prior authorization criteria (2026) (opens in a new tab)
- Fouks et al. (2021) (opens in a new tab)
- G-BA justification to the resolution on nirogacestat (2026) (opens in a new tab)
- G-BA resolution on nirogacestat (2026) (opens in a new tab)
- Garbay et al. (2012) (opens in a new tab)
- Garcia-Ortega et al. (2020) (opens in a new tab)
- Garg et al. (2022) (opens in a new tab)
- Gounder (2026b) (opens in a new tab)
- Gounder et al. (2018) (opens in a new tab)
- Gounder et al. (2020) (opens in a new tab)
- Gounder et al. (2023a) (opens in a new tab)
- Gounder et al. (2023b) (opens in a new tab)
- Gounder et al. (2023c) (opens in a new tab)
- Gounder et al. (2025) (opens in a new tab)
- Gounder et al. (2026a) (opens in a new tab)
- Gronchi et al. (2021) (opens in a new tab)
- Hamada et al. (2014) (opens in a new tab)
- Hansmann et al. (2004) (opens in a new tab)
- Hohenberger et al. (2024) (opens in a new tab)
- Huang et al. (2023) (opens in a new tab)
- Husson et al. (2019) (opens in a new tab)
- Immunome corporate presentation, October 2026 (2026) (opens in a new tab)
- Immunome expanded access policy (opens in a new tab)
- Immunome Form 10-K (2026) (opens in a new tab)
- Immunome Form 10-Q, second quarter 2026 (2026) (opens in a new tab)
- Immunome Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
- Immunome press release, EMA validation of MAA (2026) (opens in a new tab)
- Immunome press release, ESMO 2026 data (2026) (opens in a new tab)
- Immunome press release, FDA acceptance of NDA (2026) (opens in a new tab)
- Immunome press release, first quarter 2026 results (2026) (opens in a new tab)
- Immunome press release, full year 2025 results (2026) (opens in a new tab)
- Immunome press release, J.P. Morgan 2025 pipeline update (2025) (opens in a new tab)
- Immunome press release, NDA submission (2026) (opens in a new tab)
- Immunome press release, RINGSIDE data at ASCO 2026 (2026) (opens in a new tab)
- Immunome press release, RINGSIDE topline results (2025) (opens in a new tab)
- Immunome press release, second quarter 2025 results (2025) (opens in a new tab)
- Immunome press release, second quarter 2026 results (2026) (opens in a new tab)
- Immunome press release, third quarter 2025 results (2025) (opens in a new tab)
- Immunome press release, third quarter 2026 results (2026) (opens in a new tab)
- Immunome topline call presentation (2025) (opens in a new tab)
- Ingley et al. (2019) (opens in a new tab)
- Janssen et al. (2017) (opens in a new tab)
- Johns et al. (2023) (opens in a new tab)
- Kasper et al. (2017a) (opens in a new tab)
- Kasper et al. (2017b) (opens in a new tab)
- Kasper et al. (2023) (opens in a new tab)
- Kasper et al. (2024a) (opens in a new tab)
- Kasper et al. (2024b) (opens in a new tab)
- Kasper et al. (2024c) (opens in a new tab)
- Kasper et al. (2026) (opens in a new tab)
- Keus et al. (2013) (opens in a new tab)
- Kornreich et al. (2023) (opens in a new tab)
- Kubicek et al. (2026) (opens in a new tab)
- Kummar et al. (2017) (opens in a new tab)
- Kurtz et al. (2021) (opens in a new tab)
- Lazar et al. (2008) (opens in a new tab)
- Loggers et al. (2024) (opens in a new tab)
- Lucas et al. (2025) (opens in a new tab)
- Malaviya et al. (2025) (opens in a new tab)
- Mandel et al. (2022) (opens in a new tab)
- Matsunobu et al. (2020) (opens in a new tab)
- Merck KGaA annual report 2025 (2026) (opens in a new tab)
- Merck KGaA press release, first quarter 2026 results (2026) (opens in a new tab)
- Merck KGaA press release, second quarter 2026 results (2026) (opens in a new tab)
- Merck KGaA press release, third quarter 2026 results (2026) (opens in a new tab)
- National Cancer Institute Thesaurus (opens in a new tab)
- NCODA PQI in Action, nirogacestat (2025) (opens in a new tab)
- NICE TA1199 committee discussion (2026) (opens in a new tab)
- NICE TA1199 information about nirogacestat (2026) (opens in a new tab)
- NICE TA1199 recommendations (2026) (opens in a new tab)
- NICE TA1199 resource impact summary report (2026) (opens in a new tab)
- Nieuwenhuis et al. (2008) (opens in a new tab)
- Nieuwenhuis et al. (2011) (opens in a new tab)
- Nishida et al. (2015) (opens in a new tab)
- Nishida et al. (2020) (opens in a new tab)
- Noujaim et al. (2024) (opens in a new tab)
- Oregon Medicaid prior authorization criteria (2025) (opens in a new tab)
- Palassini et al. (2017) (opens in a new tab)
- Penel et al. (2011) (opens in a new tab)
- Penel et al. (2017) (opens in a new tab)
- Penel et al. (2022) (opens in a new tab)
- Penel et al. (2023) (opens in a new tab)
- Perrier et al. (2018) (opens in a new tab)
- Quast et al. (2016) (opens in a new tab)
- Quintini et al. (2012) (opens in a new tab)
- Ratan et al. (2025) (opens in a new tab)
- Ratan et al. (2026) (opens in a new tab)
- Riedel et al. (2022) (opens in a new tab)
- Rigaux et al. (2015) (opens in a new tab)
- Rutherford et al. (2026) (opens in a new tab)
- Rutkowski et al. (2026) (opens in a new tab)
- Salas et al. (2011) (opens in a new tab)
- Saraf et al. (2025) (opens in a new tab)
- Sbaraglia et al. (2021) (opens in a new tab)
- Schut et al. (2022a) (opens in a new tab)
- Schut et al. (2022b) (opens in a new tab)
- Schut et al. (2023a) (opens in a new tab)
- Schut et al. (2023b) (opens in a new tab)
- Shaikh et al. (2024) (opens in a new tab)
- Shatnawei et al. (2013) (opens in a new tab)
- Shimizu et al. (2020a) (opens in a new tab)
- Shimizu et al. (2020b) (opens in a new tab)
- Singh et al. (2026) (opens in a new tab)
- Skapek et al. (2007) (opens in a new tab)
- Skapek et al. (2013) (opens in a new tab)
- Souza et al. (2023) (opens in a new tab)
- SpringWorks Connecticut OGSIVEO price disclosure (2026) (opens in a new tab)
- SpringWorks OGSIVEO prescribing information (2026) (opens in a new tab)
- SpringWorks Therapeutics Form 10-K (2025) (opens in a new tab)
- Tan et al. (2026) (opens in a new tab)
- Thomas et al. (2026) (opens in a new tab)
- Timbergen et al. (2018) (opens in a new tab)
- Toulmonde et al. (2019) (opens in a new tab)
- van Broekhoven et al. (2015) (opens in a new tab)
- van der Graaf et al. (2026) (opens in a new tab)
- van Houdt et al. (2019) (opens in a new tab)
- Vermont Attorney General new drug report (2024) (opens in a new tab)
- Villalobos et al. (2018) (opens in a new tab)
- Wang et al. (2012) (opens in a new tab)
- Wang et al. (2026) (opens in a new tab)
- WHO Proposed INN List 130 (2023) (opens in a new tab)
- WHO Recommended INN List 92 (2024) (opens in a new tab)
- Xu et al. (2026) (opens in a new tab)
- Zare et al. (2026) (opens in a new tab)